HSIEN-YI CHIUTSEN-FANG TSAI2022-01-112022-01-1120160190-9622https://www.scopus.com/inward/record.uri?eid=2-s2.0-84974602545&doi=10.1016%2fj.jaad.2016.02.1168&partnerID=40&md5=a44cee7ba56a41532a35b36b2afd0b1bhttps://scholars.lib.ntu.edu.tw/handle/123456789/592069[SDGs]SDG3[SDGs]SDG5interleukin 17; secukinumab; dermatological agent; monoclonal antibody; secukinumab; virus DNA; clinical trial (topic); eyebrow; human; Letter; observational study; pilot study; prevalence; priority journal; prospective study; psoriasis; Psoriasis Area and Severity Index; verruca vulgaris; adult; female; genetics; isolation and purification; male; middle aged; neck; Papillomaviridae; psoriasis; severity of illness index; skin; virology; Adult; Antibodies, Monoclonal; Dermatologic Agents; DNA, Viral; Eyebrows; Female; Humans; Male; Middle Aged; Neck; Papillomaviridae; Pilot Projects; Prospective Studies; Psoriasis; Severity of Illness Index; Skinjournal article10.1016/j.jaad.2016.02.1168273175242-s2.0-84974602545